Pacific Edge (NZE:PEB, ASX:PEB) secured orders from Queensland's Townsville University Hospital for its Cxbladder Triage Plus test under a newly implemented nurse-led clinical pathway for hematuria assessment and non-muscle invasive bladder cancer surveillance, according to a Thursday filing with the Australian and New Zealand bourses.
The hospital will use Triage Plus, a urine-based RNA and DNA genomic test, to risk-stratify hematuria patients and reduce unnecessary invasive procedures, alongside Cxbladder Monitor to decrease cystoscopy frequency in recurrent bladder cancer surveillance, the filing added.
The company's Kiwi shares jumped past 6% in recent Thursday trade.